Catheter Precision (VTAK) Announces Expansion of LockeT into an Eighth European Country Since Receipt of CE Mark
Catheter Precision (NYSE:VTAK) announced on Dec 18, 2025 the first purchase order and a multi‑year commitment for its LockeT device at Mater Private Hospital in Dublin, Ireland.
Rhea-AI Summary
Catheter Precision (NYSE:VTAK) announced on Dec 18, 2025 the first purchase order and a multi‑year commitment for its LockeT device at Mater Private Hospital in Dublin, Ireland. Mater Private is described as Ireland's largest electrophysiology center, performing over 1,000 EP procedures annually. The company said LockeT was rapidly adopted during onboarding, with 52 staff trained in two days, and that a European key opinion leader helped introduce the device. The agreement represents an initial commercial expansion into an eighth European country following CE mark receipt and supports the company's international adoption strategy.
Positive
- None.
Negative
- None.
Details
News Market Reaction – VTAK
On Dec 18, the day this news came out, VTAK closed 0.91% above the previous close.
Data tracked by StockTitan Argus for the Dec 18 session.
Key Figures
- Annual EP procedures
- over 1,000 procedures
- Mater Private Hospital EP center volume
- Staff trained
- 52 staff members
- LockeT onboarding at Mater Private Hospital
- Training duration
- two days
- Time to train 52 staff on LockeT
- European expansion
- eighth European country
- LockeT footprint in Europe since CE Mark
Historical Context
-
Multi-year VIVO tender in Hungary, first installation in Central/Eastern Europe.
-
Commercial launch of LockeT in Switzerland with distribution via FuMedica AG.
-
CMS adds EP ablation codes to ASC list, framed as LockeT opportunity.
-
Rapid LockeT uptake in five South African hospitals with repeat orders.
-
Revenue growth but substantial losses and going concern warning disclosed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
electrophysiology medical
arrhythmia medical
suture retention device medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology center
Fort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a leader in advanced electrophysiology solutions, today announced the successful implementation of LockeT and the first LockeT purchase order at Mater Private Hospital, located in Dublin, Ireland. This marks a significant milestone in the company’s global expansion strategy and reinforces its commitment to improving procedural safety and efficiency in cardiac care.
Mater Private Hospital is Ireland’s largest Electrophysiology (EP) center and performs over 1,000 EP procedures annually, making it a key institution for arrhythmia treatment and innovation.
Prof. Gábor Széplaki, a leading electrophysiologist and key opinion leader in Europe, has been instrumental in introducing LockeT to Mater Private Dublin. His commitment to innovation ensures LockeT will play a vital role in advancing EP care at the center by demonstrating the product’s ability to streamline workflows.
LockeT’s ease of use and rapid adoption were evident during onboarding, with the chief nurse personally training 52 staff members in just two days—a testament to the device’s intuitive design and operational efficiency.
Fatih Ayoglu, European Sales Manager at Catheter Precision, said, "Partnering with Mater Private Dublin is a major achievement for Catheter Precision. As Ireland’s largest EP center, their multi-annual commitment to LockeT validates our technology and strengthens our position in the global electrophysiology market. The acceptance of LockeT at this hospital further underscores Catheter Precision’s focus on expanding its footprint in international markets and driving adoption of technologies that improve clinical outcomes”.
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
# # #
CONTACTS: Investor Relations 973-691-2000 IR@catheterprecision.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.